Novo Nordisk

Novo Nordisk Invests $1.09 Billion in Brazil

Novo Nordisk continues its sizeable manufacturing investments to meet increasing drug demands.

Novo Nordisk to Build New Production Facility in Odense, Denmark

Danish drugmaker Novo Nordisk plans to invest 8.5 billion Danish kroner (about €1.14 billion) to establish a new production facility in Odense, Denmark.

Ascendis Licences Proprietary Technology to Novo Nordisk

Danish biopharma company Ascendis Pharma will grant pharmaceutical giant Novo Nordisk an exclusive worldwide license to its TransCon technology platform to develop, manufacture, and commercialize proprietary products for the treatment of metabolic and cardiovascular diseases.

Novo Nordisk Pharmatech to Build New Factory in Denmark

In order to meet significantly higher demand from its parent company Novo Nordisk, Novo Nordisk Pharmatech is planning to build a new factory at a 47,000 m² site in Køge, Denmark, which it acquired in March 2023.

Novo Nordisk Invests $4 Billion to Expand US Production

Ozempic producer Novo Nordisk announced plans to invest $4.1 billion to build a second fill and finishing manufacturing facility in Clayton, North Carolina, for the production of obesity and diabetes drugs.

Novo Nordisk to Acquire Cardior Pharmaceuticals

Novo Nordisk is to acquire Cardior Pharmaceuticals for up to €1.025 billion Euros, including an upfront payment and additional payments if certain development and commercial milestones are achieved.

Novo Nordisk and Neomorph to Develop Molecular Glue Drugs

US biotechnology company Neomorph signed a $1.46 billion licensing agreement with Novo Nordisk to discover, develop and commercialize molecular glue degraders.

Novo Holdings to Acquire Catalent for $16.5 Billion

Novo Holdings, Novo Nordisk's parent company, is acquiring US contract development and manufacturing organization (CDMO) Catalent for $16.5 billion. The companies said that Novo Holdings will acquire all outstanding shares of Catalent for $63.50 per share in cash.

Novo Nordisk to Invest €2.1 Billion in French Production Site

Novo Nordisk wants to make another major capital investment in production capacity for its diabetes and obesity therapies. The Danish drugmaker announced to spend more than 16 billion Danish kroner (€2.1 billion euros) starting in 2023 to expand its production site in Chartres, France, adding aseptic production and finished production processes and an extension of the current Quality Control Laboratory.

Novo Nordisk to Invest €5.6 Billion in Expansion of API Production in Denmark

Danish drugmaker Novo Nordisk plans to invest more than 42 billion Danish kroner (about €5.6 billion) starting in 2023 to expand existing manufacturing facilities at the company’s Kalundborg, Denmark, site to meet future market demands.

Novo Nordisk to Buy Hypertension Treatment from KBP Biosciences

Novo Nordisk has agreed to acquire ocedurenone for uncontrolled hypertension with potential application in cardiovascular and kidney disease from KBP Biosciences for up to $1.3 billion.

Novo Holdings, Gurnet Point Close Acquisition of Paratek Pharmaceuticals

Novo Holdings, controlling shareholder in drugmaker Novo Nordisk, and healthcare investment firm Gurnet Point closed their acquisition of US antibiotics specialist Paratek Pharmaceuticals in a transaction valued at $462 million. Novo Holdings said that this is its largest individual investment in antimicrobial resistance (AMR) therapies to date.

Novo Nordisk to Acquire Inversago Pharma

Danish drugmaker Novo Nordisk has agreed to acquire Montreal, Canada-based Inversago Pharma. The transaction is worth up to $1.075 billion in cash if certain development and commercial milestones are achieved, the companies said in a statement.

Novo Nordisk in Talks to Take Majority Stake in Biocorp

Danish drugmaker Novo Nordisk is in exclusive talks to take a controlling stake in Biocorp, a French company specializing in developing and producing delivery systems and medical devices, for about €154 million.

Navigating Uncertainty in the Biopharma Market

Biopharma companies are facing funding challenges in 2023 as interest rates rise and investors are becoming more risk adverse. There is hope on the horizon, say some analysts, while others project a prolonged slump due to inflation and global instability. Established pharmaceutical companies are often seen as safer investments, with larger developers expected to perform well in 2023, especially if litigation threats against drugs like Zantac disappear. However, concerns about revenue gaps continue for big companies like GSK and Sanofi, and their strategy and leadership will be closely monitored in the coming months.

European Drugmakers Slam EU Reform Proposals

European NGOs have welcomed the EU’s plans for an overhaul of pharmaceutical legislation – the first in two decades – presented this week in Brussels. The drugs industry, however, has expressed sharp criticism.

Big Pharma Undercuts California Generic Insulin Plan

Plans by major insulin producers Eli Lilly, NovoNordisk and Sanofi to drop their prices may be undercutting the US state of California’s state-backed generic insulin scheme.

Sanofi in Lockstep with US Insulin Price Cuts

The world's largest insulin producers, Eli Lilly, NovoNordisk and Sanofi are now marching (almost) in lockstep to reduce US market prices, but not without tossing sideward barbs at the system.

Novo Nordisk to Cut US Insulin prices from 2024

Danish drugmaker Novo Nordisk has added its name to the list of insulin producers cutting prices for US retail buyers, following up on Eli Lilly’s announcement of price cuts and in response to growing pressure from the White House.

Bayer to Spend $1 Billion on US Drug R&D

Bayer is looking to spend $1 billion on drug research and development in the United States during 2023 as part of a plan to double its sales in the country by the end of the decade.

Lilly Insulin Price Cut Revives US Discussion

As the discussion surrounding the high price of insulin in the US continues unabated, drugmaker Eli Lilly implemented price reductions of 70% for its most commonly prescribed insulin products at the beginning of March.

Novo Nordisk Restructures R&D Services in the US

Danish pharma Novo Nordisk is expanding its R&D capabilities in Boston, Massachusetts, US, which will lead to the closure of a facility in Indianapolis and a restructuring of its Seattle operations.

Novo Nordisk Expands API Capacity

Danish pharma Novo Nordisk has announced plans to invest 5.4 billion Danish kroner to expand its existing facilities in Bagsværd.

Pharma CEOs Take Action on Climate Change

The CEOs of seven multinational pharmaceutical companies have announced that they are taking joint action to achieve near-term emissions reduction targets and accelerate the delivery of net zero health systems.

Novo Nordisk Licenses Zealand’s Diabetes Treatment

Denmark’s Novo Nordisk has entered into a global license and development with compatriot biotech Zealand Pharma for the latter’s Zegalogue (dasiglucagon) injectable diabetes treatment.

Novo Nordisk Boosts Blood Disorders with Forma Buy

Danish pharma Novo Nordisk has agreed to acquire US clinical-stage biopharma Forma Therapeutics in a deal worth $1.1 billion that will expand its blood disorders portfolio. Forma’s board of directors has unanimously approved the takeover, which is expected to close in the final quarter of 2022.

Novozymes and Novo Nordisk Partner on Enzymes

Danish companies Novozymes and Novo Nordisk Pharmatech are teaming up to develop technical enzymes to support biopharma processing. The companies aim to develop high-quality enzymatic processing aids for the regenerative medicines market, focusing on stem cell and gene therapies.

Novo Nordisk Buys Dicerna Pharmaceuticals

Danish pharma Novo Nordisk has agreed to buy Dicerna Pharmaceuticals, offering $3.3 billion for the US biopharma and its ribonucleic acid interference (RNAi) platform.

Novo Nordisk Takes Prothena’s ATTR Amyloidosis Program

Danish drugmaker Novo Nordisk has acquired Prothena’s clinical-stage stage antibody PRX004 and broader ATTR amyloidosis program, gaining full global rights to the intellectual property and related rights of the ATTR amyloidosis business and pipeline.

Novo Nordisk to Buy Emisphere Technologies

Danish drugmaker Novo Nordisk has agreed to buy US drug delivery company Emisphere Technologies for $1.8 billion.

Evotec Enters Multiple Drug Discovery Pacts

German drug discovery and development company Evotec has struck four separate partnership agreements during August.

Novo Nordisk Buys Cardio-renal Group Corvidia

Novo Nordisk to Upgrade Danish Insulin Plant

AstraZeneca Aims to be Carbon Neutral by 2025

Novo Nordisk Upgrades Danish Plant